CD28 and melanoma: TYRP1-directed chimeric antigen receptor T cells, optimized with a long flexible hinge and CD28 co-stimulation, exhibit potent efficacy against cutaneous and rare melanoma subtypes in preclinical models by targeting high surface TYRP1 expression;[39] 3.